MA55305A - Anticorps bispécifiques anti-v béta 17/anti-cd123 - Google Patents

Anticorps bispécifiques anti-v béta 17/anti-cd123

Info

Publication number
MA55305A
MA55305A MA055305A MA55305A MA55305A MA 55305 A MA55305 A MA 55305A MA 055305 A MA055305 A MA 055305A MA 55305 A MA55305 A MA 55305A MA 55305 A MA55305 A MA 55305A
Authority
MA
Morocco
Prior art keywords
beta
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
MA055305A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Iqbal S Grewal
Manuel Alejandro Sepulveda
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA55305A publication Critical patent/MA55305A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA055305A 2019-03-11 2020-03-11 Anticorps bispécifiques anti-v béta 17/anti-cd123 MA55305A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11

Publications (1)

Publication Number Publication Date
MA55305A true MA55305A (fr) 2022-01-19

Family

ID=71670296

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055305A MA55305A (fr) 2019-03-11 2020-03-11 Anticorps bispécifiques anti-v béta 17/anti-cd123

Country Status (12)

Country Link
US (1) US20220127359A1 (fr)
EP (1) EP3937977A2 (fr)
JP (1) JP2022523442A (fr)
KR (1) KR20210138033A (fr)
CN (1) CN113874400A (fr)
AU (1) AU2020235475A1 (fr)
BR (1) BR112021017801A2 (fr)
CA (1) CA3132916A1 (fr)
IL (1) IL286147A (fr)
MA (1) MA55305A (fr)
MX (1) MX2021010857A (fr)
WO (1) WO2020183245A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
UY39373A (es) * 2020-08-10 2022-02-25 Janssen Biotech Inc Materiales y métodos para producir linfocitos específicos de virus diseñados mediante bioingeniería
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
CA3194752A1 (fr) * 2020-09-11 2022-03-17 Janssen Biotech, Inc. Molecules de ciblage immunitaires multispecifiques et leurs utilisations
CA3237038A1 (fr) * 2021-11-01 2023-05-04 Janssen Biotech, Inc. Compositions et methodes destinees a la modulation de l'immunite a mediation par chaine beta
WO2023152633A1 (fr) * 2022-02-09 2023-08-17 Janssen Biotech, Inc. Procédés et compositions comprenant des activateurs de lymphocytes t bispécifiques v bêta 17 et des lymphocytes spécifiques de virus modifiés par génie biologique

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6084087A (en) * 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
DK1015576T3 (da) 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (fr) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Procédé pour la production de polypeptide au moyen de la régulation d'un ensemble
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP2035456A1 (fr) 2006-06-22 2009-03-18 Novo Nordisk A/S Production d'anticorps bispécifiques
CA2759233C (fr) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Procede de fabrication de molecules heteromultimeres
KR102152109B1 (ko) 2010-04-20 2020-09-07 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
MX358862B (es) 2011-11-04 2018-09-06 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
WO2013131001A1 (fr) * 2012-03-02 2013-09-06 Academia Sinica Anticorps anti-molécules d'adhérence cellulaire épithéliale (epcam) et leurs procédés d'utilisation
ME03724B (fr) * 2014-09-05 2021-01-20 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN111344303A (zh) * 2017-06-01 2020-06-26 Xencor股份有限公司 结合cd123和cd3的双特异性抗体

Also Published As

Publication number Publication date
BR112021017801A2 (pt) 2022-01-18
CA3132916A1 (fr) 2020-09-17
MX2021010857A (es) 2021-12-15
KR20210138033A (ko) 2021-11-18
WO2020183245A2 (fr) 2020-09-17
AU2020235475A1 (en) 2021-09-30
US20220127359A1 (en) 2022-04-28
IL286147A (en) 2021-10-31
WO2020183245A3 (fr) 2020-12-03
CN113874400A (zh) 2021-12-31
EP3937977A2 (fr) 2022-01-19
JP2022523442A (ja) 2022-04-22

Similar Documents

Publication Publication Date Title
MA55305A (fr) Anticorps bispécifiques anti-v béta 17/anti-cd123
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA50505A (fr) Anticorps 2 + 1 bispécifiques (contorsbodies)
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA43197A (fr) Constructions d'anticorps bispécifiques pour cdh3 et cd3
MA47609A (fr) Anticorps anti-il31 à usage vétérinaire
MA51903A (fr) Formulations d'anticorps b7-h4
MA44054A (fr) Plateforme d'anticorps bispécifique
MA52152A (fr) Anticorps
MA53905A (fr) Anticorps stabilisant trem2
MA49250A (fr) Nouveaux anticorps anti-cd3
MA54052A (fr) Formulation d'anticorps
MA55877A (fr) Ensemble raidisseur de compensation
MA55705A (fr) Anticorps bispécifiques
ZA202004908B (en) Bispecific antibody
MA51902A (fr) Schémas posologiques d'anticorps b7-h4
IL290267A (en) Bispecific antibodies are directed against cd3
MA55491A (fr) Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
MA56466A (fr) Anticorps anti-epha4
IL282355A (en) Bispecific antibodies directed to exosomes
MA55600A (fr) Anticorps anti-ige
MA50222A (fr) Anticorps bispécifiques anti-pd-l1-anti-tim-3
MA50654A (fr) Anticorps anti-pacap
IL286918A (en) Bispecific antibody